Recently, the first Chinese Medicine Ecology Conference and Chinese Medicine Industry Expo (hereinafter referred to as the Chinese Medicine Ecology Conference) was successfully concluded in Shenzhen.
At the TCM Ecological Conference, the certification and selection of "2023 TOP50 Comprehensive Competitiveness Index of Chinese Patent Medicine Enterprises", "2023 'Three Nothings' Brand Varieties of Chinese Herbal Medicine", "2023 Chinese Herbal Medicine Brand Demonstration Base", and "2023 Top 30 Chinese Medicine Decoction Pieces Brand Development Index" were carried out. During the meeting, Sinopharm Taiji, as the co-founder of the Chinese Medicine Ecological Conference, had a wonderful corporate booth and a brilliant corporate brand, winning 3 awards in one fell swoop!
Sinopharm Taiji was included in the "Top 50 Comprehensive Competitiveness Index of Chinese Patent Medicine Enterprises in 2023".
On the evening of December 15, the "2023 TOP50 Comprehensive Competitiveness Index of Chinese Patent Medicine Enterprises" was grandly released at the first Chinese Medicine Ecology Conference, and Sinopharm Taiji was successfully listed, ranking 12th. Sinopharm Taiji is a large-scale pharmaceutical group covering pharmaceutical research and development, industrial production, pharmaceutical business, health industry and other fields, integrating science, industry and trade. In recent years, Sinopharm Taiji has focused on digital transformation and technological innovation through reform measures such as standardized governance, scientific management, strategic adjustment and cultural reshaping, and has achieved remarkable results in industrial development, economic benefits and brand building, and the comprehensive competitiveness of the enterprise has been greatly improved.
The Chinese medicine Taiji Atractylodes variety won the "2023 Chinese herbal medicine 'three nos' brand variety".
The "three-in-one-all" brand variety base is an award organized by the National Alliance for Standardization and Quality Assessment Innovation of Chinese Herbal Medicine to organize authoritative experts for unified verification and selection, and it is currently the industry's highest quality requirements, the strictest standards and the most authoritative certification. Sinopharm Taiji Fuling Pharmaceutical Factory Cangzhu Base is the first Sinopharm Taiji brand base to be certified by the industry, and it is also the first base in Chongqing to obtain this certification. The construction of the "three nos" brand variety base is to control the quality of Chinese herbal medicines from the source, and it is also to implement the first workshop concept of using the planting base as a raw material. Sinopharm Taiji Fuling Pharmaceutical Factory strictly implements the operation specification of "Development and Application of Standardized Production Technology of Atractylodes", upgrades the quality management of the base, integrates the management concept of "three nos", establishes and improves the quality management system of brand building of Atractylodes atractylodes base, and the GAP traceability platform of Chinese herbal medicines, and submits an application for the certification of Atractylodes atractylodes "three nos" base to the alliance in 2023. After the on-site verification and centralized review and verification of relevant experts organized by the alliance, all of them meet the quality requirements of "three nos and one perfect", marking that Atractylodes atractylodes has achieved sulfur-free processing, no aflatoxin pollution, no pollution (including no excessive pesticide residues, no excessive heavy metals, and no use of growth regulators to promote the growth of harvested organs) and the whole process can be traced, so as to fully ensure the quality and safety of Atractylodes medicinal materials.
Sinopharm Taiji Golden Buckwheat Production Base was awarded the "2023 Chinese Herbal Medicine Brand Demonstration Base".
Golden buckwheat is one of the main raw materials of the Sinopharm Taiji fist product "Rush Syrup", and the dosage is large. Since 1996, Sinopharm Taiji has carried out research on the investigation of golden buckwheat resources, breeding methods, planting years, formula fertilization technology, pest control, harvesting and processing technology, and golden buckwheat quality, and has found out the distribution of wild resources of golden buckwheat in China and the planting technology of systematic wild variants, and continuously improved the economic benefits of artificial planting 1374.95-2021) - Technical Regulations for the Standardized Production of Golden Buckwheat", focusing on the comprehensive development and utilization of "medicine-food-feeding" of golden buckwheat, effectively enhancing the competitiveness and added value of products. Since 2000, the construction of golden buckwheat planting base in the Dao real estate area has been completed, with a total of 250,000 mu of golden buckwheat planted, of which from 2022 to 2023, 35,000 mu of standardized planting base and 500 mu of improved seed breeding base will be built in Youyang, Dianjiang, Wanzhou, Fuling and other places in Chongqing, with an output of 3,210 tons, an output value of 33.7 million yuan, and 5,760 farmers.
Sinopharm Taiji attaches great importance to the resources of Chinese herbal medicines, pays attention to the certification of "three nos and one perfect" varieties of Chinese herbal medicines, and the construction of brand bases, and builds "4G, one code, one center and one platform (i.e., GAP for medicinal material planting, GMP production, GSP operation and drug clinical trial GCP, full quality traceability code and smart decoction center and smart medical platform)" around "one digital Taiji", and builds a whole industry chain development system. Guided by high-quality Chinese medicinal materials, we adhere to the concept of "authentic planting and full traceability". At present, Sinopharm Taiji has built a standardized planting base of 300,000 mu of Chinese herbal medicines, effectively ensuring the quality of the source of decoction pieces, and laying a solid foundation for the industrialization, modernization and internationalization of traditional Chinese medicine.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.